Japan's Yakult Honsha has expanded a collaborative R&D and commercialisation agreement with Proacta to include another of the private US firm's hypoxia-activated prodrugs for cancer.
Yakult acquired exclusive development and commercialisation rights in Japan to Proacta's irreversible multi-kinase inhibitor (MKI) PR509 earlier this year (
Welcome to Scrip
Create an account to read this article
Already a subscriber?